Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline agrees deal with Medivir over cold sore treatment

GlaxoSmithKline agrees deal with Medivir over cold sore treatment

24th June 2010

GlaxoSmithKline has agreed a new deal with Medivir which will allows it to gain exclusive marketing rights to the cold sore treatment Xerclear.

The deal will see GlaxoSmithKline offer an upfront payment of three million euros (2.5 million pounds) to commercialise the over-the-counter (OTC) product in regions such as Europe, while it will also fund all future development of the product in the affected territories.

Xerclear has been approved across 14 European nations since October 2009 based on positive clinical data and is the only topical herpes labialis treatment clinically proven to help prevent the appearance of lesions.

John Clarke, president of consumer healthcare at GlaxoSmithKline, said the deal will help it to augment its dermatology offering in a number of key areas.

He added: “This alliance demonstrates GlaxoSmithKline’s ongoing commitment to invest in and expand our OTC business.”

This comes after the company agreed a deal with Beiersdorf subsidiary Labtec earlier this week to acquire marketing rights for another cold sore treatment, which will be based on the LabiPatch platform technology.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.